Health Care & Life Sciences » Pharmaceuticals | Pharmesis International Ltd.

Pharmesis International Ltd. | Income Statement

Fiscal year is January-December. All values SGD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
13,165.00
12,511.80
13,653.90
14,306.00
14,242.90
13,118.20
Cost of Goods Sold (COGS) incl. D&A
5,418.70
5,746.40
6,360.20
7,946.30
7,816.30
6,738.30
Gross Income
7,746.30
6,765.40
7,293.70
6,359.60
6,426.60
6,379.90
SG&A Expense
7,587.90
7,542.10
7,125.40
7,041.10
6,607.60
6,014
EBIT
158.40
776.60
168.30
681.40
181.00
365.80
Unusual Expense
-
754.60
89.10
259.10
52.50
260.20
Non Operating Income/Expense
5.30
36.20
559.90
166.10
122.00
776.50
Interest Expense
-
87.20
207.90
181.80
178.50
180.50
Pretax Income
196.00
946.30
685.80
904.40
262.70
1,246.30
Income Tax
-
7.60
1.50
145.30
110.30
214.70
Consolidated Net Income
196.00
953.90
684.20
1,049.70
373.00
1,031.60
Net Income
96.70
782.40
535.90
964.30
506.00
262.80
Net Income After Extraordinaries
96.70
782.40
535.90
964.30
506.00
262.80
Net Income Available to Common
96.70
782.40
535.90
964.30
506.00
262.80
EPS (Basic)
0.00
0.04
0.03
0.04
0.02
0.01
Basic Shares Outstanding
20,000.00
20,000.00
20,748.00
23,000.00
23,000.00
23,000
EPS (Diluted)
0.00
0.04
0.03
0.04
0.02
0.01
Diluted Shares Outstanding
20,000.00
20,000.00
20,748.00
23,000.00
23,000.00
23,000
EBITDA
874.00
230.70
531.70
380.30
104.20
651.90
Non-Operating Interest Income
32.40
636.00
254.50
52.00
27.40
24.30
Minority Interest Expense
99.30
171.50
148.40
85.40
133.00
768.80

About Pharmesis International

View Profile
Address
No. 8 Yingbin Road
Chengdu Sichuan 611331
China
Employees -
Website http://www.pharmesis.com
Updated 07/08/2019
Pharmesis International Ltd. Is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine (TCM) Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand.